Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Genecentrix Inc
Profile last edited on: 11/11/2019      CAGE: 6PXF4      UEI: YZ3PJYMC1UV9

Business Identifier: Bioinformatics for early-stage drug discovery
Year Founded
2012
First Award
2015
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

175 Varick Street 4th Floor
New York, NY 10014
   (917) 289-0949x111
   info@genecentrix.com
   www.genecentrix.com
Location: Single
Congr. District: 10
County: New York

Public Profile

GeneCentrix Inc is a bioinformatics company that builds tools for early-stage drug discovery. The company is focused on developing in silico methods to rapidly identify drug targets and drug candidates for any given disease and phenotype. The company uses the integration of heterogeneous big biomedical data sets to identify elusive relationships between drugs and protein targets.

Extent of SBIR involvement

User Avatar
Phase I Awards
4
Phase II Awards
3
Conversion Rate
75.00%
Phase I Dollars
$650,001
Phase II Dollars
$2,247,236
Total Awarded
$2,897,237

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 2 NIH $316,720
Project Title: Leveraging AI to discover neuron-targeted anti-addiction drugs
2020 2 NIH $1,622,754
Project Title: BD2K Product for Enhancing Phenotypic Screens
2017 1 NIH $150,000
Project Title: BD2K product for enhancing phenotypic screens
2016 2 NIH $807,763
Project Title: Novel Tool for Linking Drugs and Phenotypes

Key People / Management

  Doreen Tivon -- CEO

  Klara O Felsovalyi -- Co-Founder

  Jennifer Fuller

  Eric Ni -- Sofeware Developer

  Lauren Meredith Young

Company News

There are no news available.